Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts

Shane E. Holloway, Adam W. Beck, Latha Shivakumar, Jessica Shih, Jason B. Fleming, Rolf A. Brekken

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, is critical for growth of human pancreatic adenocarcinoma. Preclinical studies demonstrate that blockade of VEGF activity can control the growth of pancreatic tumors in mice. In this study, we evaluated the efficacy of 2C3, an antibody that inhibits VEGF receptor 2 activation by human VEGF, to inhibit the growth of human pancreatic adenocarcinoma in mice. Methods: Human pancreatic cancer cell lines (MiaPaca-2, Panc-1, and Capan-1) were used to establish xenografts in nu/nu mice. The expression of VEGF and its receptors was determined in each cell line. Proliferation of tumor cells in vitro and tumor growth in vivo in the presence of 2C3 or a control antibody was evaluated. The effect of 2C3 on tumor weight, total vessel density, number of pericyte-associated vessels, and tumor perfusion was determined, and the level of 2C3 in the serum of animals was measured by enzyme-linked immunosorbent assay. Results: 2C3 did not affect the proliferation of cells in culture. 2C3 was present and active in the serum of tumor-bearing animals treated with 2C3, and these animals showed a decrease in tumor burden compared with control-treated mice. Therapy with 2C3 resulted in reduced vascular function, measured by a decrease in vessel density and in the percentage of vessels associated with pericytes. Furthermore, tumors derived from Capan-1 cells demonstrated decreased perfusion after treatment with 2C3. Conclusions: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice. Published by Springer Science+Business Media, Inc.

Original languageEnglish (US)
Pages (from-to)1145-1155
Number of pages11
JournalAnnals of Surgical Oncology
Volume13
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Neoplasm Antibodies
Vascular Endothelial Growth Factor Receptor-2
Heterografts
Vascular Endothelial Growth Factor A
Adenocarcinoma
Growth
Neoplasms
Pericytes
Tumor Burden
Cell Line
Perfusion
Vascular Endothelial Growth Factor Receptor
Antibodies
Serum
Pancreatic Neoplasms
Blood Vessels
Cell Culture Techniques
Enzyme-Linked Immunosorbent Assay
Cell Proliferation

Keywords

  • Angiogenesis
  • Monoclonal antibody
  • Pancreatic cancer
  • Therapy
  • VEGF

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. / Holloway, Shane E.; Beck, Adam W.; Shivakumar, Latha; Shih, Jessica; Fleming, Jason B.; Brekken, Rolf A.

In: Annals of Surgical Oncology, Vol. 13, No. 8, 08.2006, p. 1145-1155.

Research output: Contribution to journalArticle

@article{91ad4e52b3a846c993caca4fc94954a6,
title = "Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts",
abstract = "Background: Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, is critical for growth of human pancreatic adenocarcinoma. Preclinical studies demonstrate that blockade of VEGF activity can control the growth of pancreatic tumors in mice. In this study, we evaluated the efficacy of 2C3, an antibody that inhibits VEGF receptor 2 activation by human VEGF, to inhibit the growth of human pancreatic adenocarcinoma in mice. Methods: Human pancreatic cancer cell lines (MiaPaca-2, Panc-1, and Capan-1) were used to establish xenografts in nu/nu mice. The expression of VEGF and its receptors was determined in each cell line. Proliferation of tumor cells in vitro and tumor growth in vivo in the presence of 2C3 or a control antibody was evaluated. The effect of 2C3 on tumor weight, total vessel density, number of pericyte-associated vessels, and tumor perfusion was determined, and the level of 2C3 in the serum of animals was measured by enzyme-linked immunosorbent assay. Results: 2C3 did not affect the proliferation of cells in culture. 2C3 was present and active in the serum of tumor-bearing animals treated with 2C3, and these animals showed a decrease in tumor burden compared with control-treated mice. Therapy with 2C3 resulted in reduced vascular function, measured by a decrease in vessel density and in the percentage of vessels associated with pericytes. Furthermore, tumors derived from Capan-1 cells demonstrated decreased perfusion after treatment with 2C3. Conclusions: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice. Published by Springer Science+Business Media, Inc.",
keywords = "Angiogenesis, Monoclonal antibody, Pancreatic cancer, Therapy, VEGF",
author = "Holloway, {Shane E.} and Beck, {Adam W.} and Latha Shivakumar and Jessica Shih and Fleming, {Jason B.} and Brekken, {Rolf A.}",
year = "2006",
month = "8",
doi = "10.1245/ASO.2006.05.049",
language = "English (US)",
volume = "13",
pages = "1145--1155",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts

AU - Holloway, Shane E.

AU - Beck, Adam W.

AU - Shivakumar, Latha

AU - Shih, Jessica

AU - Fleming, Jason B.

AU - Brekken, Rolf A.

PY - 2006/8

Y1 - 2006/8

N2 - Background: Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, is critical for growth of human pancreatic adenocarcinoma. Preclinical studies demonstrate that blockade of VEGF activity can control the growth of pancreatic tumors in mice. In this study, we evaluated the efficacy of 2C3, an antibody that inhibits VEGF receptor 2 activation by human VEGF, to inhibit the growth of human pancreatic adenocarcinoma in mice. Methods: Human pancreatic cancer cell lines (MiaPaca-2, Panc-1, and Capan-1) were used to establish xenografts in nu/nu mice. The expression of VEGF and its receptors was determined in each cell line. Proliferation of tumor cells in vitro and tumor growth in vivo in the presence of 2C3 or a control antibody was evaluated. The effect of 2C3 on tumor weight, total vessel density, number of pericyte-associated vessels, and tumor perfusion was determined, and the level of 2C3 in the serum of animals was measured by enzyme-linked immunosorbent assay. Results: 2C3 did not affect the proliferation of cells in culture. 2C3 was present and active in the serum of tumor-bearing animals treated with 2C3, and these animals showed a decrease in tumor burden compared with control-treated mice. Therapy with 2C3 resulted in reduced vascular function, measured by a decrease in vessel density and in the percentage of vessels associated with pericytes. Furthermore, tumors derived from Capan-1 cells demonstrated decreased perfusion after treatment with 2C3. Conclusions: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice. Published by Springer Science+Business Media, Inc.

AB - Background: Vascular endothelial growth factor (VEGF), a key regulator of angiogenesis, is critical for growth of human pancreatic adenocarcinoma. Preclinical studies demonstrate that blockade of VEGF activity can control the growth of pancreatic tumors in mice. In this study, we evaluated the efficacy of 2C3, an antibody that inhibits VEGF receptor 2 activation by human VEGF, to inhibit the growth of human pancreatic adenocarcinoma in mice. Methods: Human pancreatic cancer cell lines (MiaPaca-2, Panc-1, and Capan-1) were used to establish xenografts in nu/nu mice. The expression of VEGF and its receptors was determined in each cell line. Proliferation of tumor cells in vitro and tumor growth in vivo in the presence of 2C3 or a control antibody was evaluated. The effect of 2C3 on tumor weight, total vessel density, number of pericyte-associated vessels, and tumor perfusion was determined, and the level of 2C3 in the serum of animals was measured by enzyme-linked immunosorbent assay. Results: 2C3 did not affect the proliferation of cells in culture. 2C3 was present and active in the serum of tumor-bearing animals treated with 2C3, and these animals showed a decrease in tumor burden compared with control-treated mice. Therapy with 2C3 resulted in reduced vascular function, measured by a decrease in vessel density and in the percentage of vessels associated with pericytes. Furthermore, tumors derived from Capan-1 cells demonstrated decreased perfusion after treatment with 2C3. Conclusions: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice. Published by Springer Science+Business Media, Inc.

KW - Angiogenesis

KW - Monoclonal antibody

KW - Pancreatic cancer

KW - Therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33748356246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748356246&partnerID=8YFLogxK

U2 - 10.1245/ASO.2006.05.049

DO - 10.1245/ASO.2006.05.049

M3 - Article

C2 - 16791450

AN - SCOPUS:33748356246

VL - 13

SP - 1145

EP - 1155

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -